(MedPage Today) — In a study presented at the recent American Society of Clinical Oncology (ASCO) annual meeting, investigational tasquinimod showed early activity in relapsed/refractory multiple myeloma, with responses in patients resistant to…
Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116285
Author :
Publish date : 2025-06-27 15:42:00
Copyright for syndicated content belongs to the linked Source.
